The prevalence of COVID-19 infection in patients with multiple sclerosis (MS): a systematic review and meta-analysis.

Published on Jun 7, 2021in Neurological Sciences3.307
路 DOI :10.1007/S10072-021-05373-1
Abdorreza Naser Moghadasi14
Estimated H-index: 14
(Tehran University of Medical Sciences),
Omid Mirmosayyeb12
Estimated H-index: 12
(Tehran University of Medical Sciences)
+ 2 AuthorsMahsa Ghajarzadeh17
Estimated H-index: 17
(Tehran University of Medical Sciences)
BACKGROUND: The prevalence of COVID-19 is different in studies conducted in different countries. The aim of this systematic review and meta-analysis is to estimate the pooled prevalence of COVID-19 in patients with MS. METHODS: Two independent researchers independently searched PubMed, Scopus, EMBASE, Web of Science, and google scholar along with gray literature up to April 2021. The search strategy included the MeSH and text words as (((coronavirus OR Wuhan coronavirus OR novel coronavirus OR coronavirus disease OR COVID-19 OR 2019 novel coronavirus infection OR 2019-nCOV OR severe acute respiratory syndrome coronavirus 2 OR SARS-CoV-2) AND (Multiple Sclerosis OR Sclerosis, Multiple) OR Sclerosis, Disseminated) OR Disseminated Sclerosis) OR MS (Multiple Sclerosis)) OR Multiple Sclerosis, Acute Fulminating). RESULTS: We found 1466 articles by literature search, and after deleting duplicates, 1029 remained. Twelve articles remained for meta-analysis. Totally, 101,462 patients were evaluated and the total number of possible/confirmed cases was 1394. Mean age ranged from 35 to 54聽years. Totally, 49 patients died. The pooled prevalence of suspected COVID-19 in MS patients was 4% (95% CI: 3-4%) (I2 = 98.5%, P < 0.001). The pooled prevalence of hospitalization in infected cases was 10% (95% CI: 7-12%) (I2 = 95.6%, P < 0.001). The pooled prevalence of death in hospitalized cases was 4% (95% CI: 1-6%) (I2 = 82.4%, P < 0.001). CONCLUSION: Hospitalization rate is higher among MS patients based on COVID-19 infection while the pooled infection rate is estimated as 4%.
馃摉 Papers frequently viewed together
#1Anthony T. Reder (U of C: University of Chicago)H-Index: 61
#2Diego Centonze (University of Rome Tor Vergata)H-Index: 96
Last. Carl de Moor (Biogen Idec)H-Index: 6
view all 14 authors...
BACKGROUND: Disease-modifying therapies (DMTs) for multiple sclerosis (MS) target immunity and have the potential to increase the risk of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection and alter its clinical course. We assessed these risks in patients with MS (PwMS). OBJECTIVE: The objective of this study was to describe the overall risk of coronavirus disease 2019 (COVID-19) infection, severe disease course, and potential population-level predictors of COVID-19 infection...
OBJECTIVE: To assess the impact of immunosuppressive and immunomodulatory therapies on the severity of Coronavirus disease 2019 (Covid-19) in people with MS (PwMS). METHODS: We retrospectively collected data of PwMS with suspected or confirmed Covid-19. All the patients had complete follow up to death or recovery. Severe Covid-19 was defined by a 3-level variable: mild disease not requiring hospitalization vs pneumonia or hospitalization vs Intensive Care Unit (ICU) admission or death. We evalua...
#1Maria Sep煤lveda (University of Barcelona)H-Index: 19
#2Sara LlufriuH-Index: 25
Last. Albert Saiz (University of Barcelona)H-Index: 59
view all 18 authors...
OBJECTIVE To investigate the incidence of coronavirus disease 2019 (COVID-19) in a single-center cohort of patients with MS and to explore the contribution of their comorbidities and therapies to the outcome. METHODS A cross-sectional mixed-method study was conducted involving an email-based, self-administered questionnaire sent on May 21, 2020, to 586 patients with MS followed at the MS Unit of Hospital Clinic, University of Barcelona, along with telephone interview, and review of electronic me...
#1Sukanthi Kovvuru (University of Arkansas for Medical Sciences)H-Index: 4
#2Krishna Nalleballe (University of Arkansas for Medical Sciences)H-Index: 8
Last. Bhaskar Roy (Yale University)H-Index: 12
view all 12 authors...
Abstract Objective To study the risk of acquiring Corona Virus Disease 2019 (COVID-19) and its outcomes in patients on immunosuppressive therapy (IST) for chronic autoimmune neuromuscular disorders (aNMD) and multiple sclerosis (MS). Methods We used TriNetX, a global health collaborative clinical research platform collecting real-time electronic medical records data, which has one of the largest known global COVID-19 database. We included patients with chronic autoimmune neuromuscular disorders ...
#1Nikos Evangelou (University of Nottingham)H-Index: 38
#2Afagh Garjani (NUH: Nottingham University Hospitals NHS Trust)H-Index: 3
Last. Richard NicholasH-Index: 11
view all 19 authors...
In the early phases of the UK COVID-19 outbreak, in the absence of clear evidence about the risks for people with multiple sclerosis (pwMS) and those taking immunomodulatory disease-modifying therapies (DMT), we launched a community-based study as part of the UK MS Register (UKMSR). We intended to capture the picture of COVID-19 among pwMS and their risk of contracting the disease. Here, we report our findings from 17 March to 24 April 2020. The COVID-19 study ( is...
#1Peter M Fernandes (Edin.: University of Edinburgh)H-Index: 6
#2Martin O鈥橬eillH-Index: 2
Last. David Hunt (Edin.: University of Edinburgh)H-Index: 20
view all 8 authors...
Background: The impact of the coronavirus disease 2019 (COVID-19) pandemic on people with multiple sclerosis (MS) is a major current concern, in particular the risk of death. Here we describe the impact of the first wave of COVID-19 infections (Mar 2020-July 2020) on the Scottish MS Register (SMSR) population, a cohort of 4702 individuals with MS, all newly diagnosed in the past decade. Methods: We established a clinician alert system, linking the SMSR with the Electronic Communication of Survei...
view all 3 authors...
#1Andre C. Vogel (Harvard University)H-Index: 6
#2H. SchmidtH-Index: 9
Last. Farrah J. Mateen (Harvard University)H-Index: 32
view all 5 authors...
ABSTRACT Background People with multiple sclerosis (PwMS) experienced changes in health behaviors and access to MS care due to the COVID-19 pandemic. The USA has the highest recognized number of Covid19 infections globally. The extent of the impact of COVID-19 has not been well characterized in large samples of PwMS to date. The MS patient perspective on COVID-19 would complement the physician-reported cases of MS and COVID-19 in the literature. Methods A cross-sectional survey of adult PwMS was...
Objective To report outcomes on patients with multiple sclerosis (MS) and related disorders with coronavirus disease 2019 (COVID-19) illness. Methods From March 16 to April 30, 2020, patients with MS or related disorders at NYU Langone MS Comprehensive Care Center were identified with laboratory-confirmed or suspected COVID-19. The diagnosis was established using a standardized questionnaire or by review of in-patient hospital records. Results We identified 76 patients (55 with relapsing MS, of ...
Cited By1
#1Reza Jalili Khoshnood (Shahid Beheshti University of Medical Sciences and Health Services)H-Index: 5
#2Alireza Zali (Shahid Beheshti University of Medical Sciences and Health Services)H-Index: 18
Last. Omid Mirmosayyeb (IUMS: Isfahan University of Medical Sciences)H-Index: 12
view all 7 authors...
BACKGROUND: Patients with Parkinson's disease (PD) are at higher risk of COVID-19 infection as most of them are at older age. The goal of this study is to update the pooled prevalence of COVID-19 infection in patients with PD. METHODS: Two researchers systematically searched PubMed, Scopus, EMBASE, Web of Science, Google Scholar, and also gray literature including references of the included studies which were published before September 2021. We extracted data regarding the total number of partic...
Abstract null null Background null Outcomes of COVID-19 in PwMS (persons with Multiple Sclerosis) on immunosuppressive therapies, particularly B-cell depletors, can be unpredictable. There has been a concern for postponing or avoiding use of Rituximab (RTX) during the COVID-19 pandemic. We report the course and outcomes of COVID-19 in PwMS receiving RTX. null null null Methods null PwMS receiving RTX who contracted COVID-19 were closely monitored by tele-consultation and/or evaluated during hosp...
#1Mahdi Barzegar (IUMS: Isfahan University of Medical Sciences)H-Index: 8
#2Omid Mirmosayyeb (IUMS: Isfahan University of Medical Sciences)H-Index: 12
Last. Nasrin Asgari (University of Southern Denmark)H-Index: 26
view all 8 authors...
Abstract null null Background null We conducted this systematic review and meta-analysis to assess the risk of coronavirus disease (COVID-19), clinical features and outcome among patients with Neuromyelitis Optica Spectrum Disorder (NMOSD). null null null Methods null We systematically searched PubMed, Scopus, Web of Science, and Embase from December 1, 2019, to July 2, 2021. The gray literature including the references of original studies, review studies, conference abstracts, and WHO COVID-19 ...
#1Fereshteh Ghadiri (Tehran University of Medical Sciences)H-Index: 4
#2Mohammad Ali Sahraian (Tehran University of Medical Sciences)H-Index: 56
Last. Abdorreza Naser Moghadasi (Tehran University of Medical Sciences)H-Index: 14
view all 4 authors...
Abstract null null Background null At this time vaccination against SARS-CoV2 is a global priority. Cases with multiple sclerosis (MS) were among the first vaccinated populations in Iran. We evaluated the change in the frequency of COVID-19 after vaccination and the associated factors with severe COVID-19 infection before and after full vaccination. null null null Methods null A questionnaire was validated to investigate the basic characteristics (age, gender, education, body mass index, smoking...
#1Mahdi Barzegar (IUMS: Isfahan University of Medical Sciences)H-Index: 8
#2bagherieh S (IUMS: Isfahan University of Medical Sciences)H-Index: 1
Last. Aram Zabeti (UC: University of Cincinnati)H-Index: 4
view all 9 authors...
Background: We conducted this systematic review to identify factors associated with coronavirus disease (COVID-19) susceptibility and outcomes among people with multiple sclerosis (MS). Methods: Available studies from PubMed, Scopus, EMBASE, Web of Science, and gray literature including reference list and conference abstracts were searched from December 1, 2019, through April 12, 2021. We included cross-sectional, case-control, and cohort studies that reported risk factors of contracting COVID-1...
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.